Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Somnus Therapeutics

Request full access

Private drug development company developing an improved therapeutic to address the need of insomnia patients

Bedminster Township, United StatesFounded 2007Biotech & Life Sciences

About Somnus Therapeutics

Somnus Therapeutics, Inc. operated as a specialty pharmaceutical company with a focused, virtual model centered on a single asset. Founded in the summer of 2007 by Gary Cupit in partnership with the life sciences venture capital firm Care Capital, the company was established to address a specific unmet need in the insomnia market. Mr. Cupit, who served as CEO, brought over two decades of pharmaceutical industry experience to the venture, including senior roles at Novartis and as CEO of Sapphire Therapeutics. The company's strategy was to in-license and develop a single drug candidate through mid-stage clinical trials before out-licensing or selling the asset for final development and commercialization.

The company's core business revolved around its sole product, SKP-1041, a novel controlled-release formulation of zaleplon. Somnus secured exclusive worldwide development and commercialization rights for this therapeutic from SkyePharma in June 2007. The product utilized SkyePharma's proprietary Geoclock™ technology, a press-coated tablet designed to delay the release of the active ingredient for a predetermined period. This feature was specifically aimed at patients who suffer from sleep maintenance insomnia, meaning they can fall asleep but awaken in the middle of the night. The delayed-release mechanism was intended to allow patients to fall asleep naturally, with the medication taking effect later to prevent nocturnal awakenings, without causing next-day cognitive impairment.

Somnus Therapeutics' business model was funded through venture capital. After initial seed money from Care Capital, the company raised $15 million in a Series A financing round on February 11, 2010. The round was led by CTI Life Sciences Fund and included Care Capital. This funding was primarily allocated to finance a Phase II clinical trial for SKP-1041. In June 2011, the company announced the successful completion of this Phase 2 dose-ranging study, which met its primary endpoint for improving wake after sleep onset (WASO). Following these positive results, and in line with its initial strategy, Somnus began seeking a buyer or partner to take the drug through Phase III trials and to market. Despite the successful clinical milestone, the company ultimately ceased operations in January 2016.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2007
Headquarters
Bedminster Township, United States
Employees
1
Open positions
None listed
Dealroom signal
22.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Feb 2010 $15M $60M CTI Life Sciences —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Somnus Therapeutics website traffic

Latest recorded traffic for Somnus Therapeutics is 200 monthly website visits, up 11.1% over the last three months. Somnus Therapeutics's team grew 0% over the past year.

Latest monthly visits200 3-month web change+11.1% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Somnus Therapeutics in the Bedminster Township ecosystem

Live from Dealroom

The Somnus Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • CTI Life Sciences
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Bedminster Township HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Somnus Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Somnus Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.